A Phase 1/2a Study of DB-1310 in Advanced/Metastatic Solid Tumors
Status:
Not yet recruiting
Trial end date:
2026-08-31
Target enrollment:
Participant gender:
Summary
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and
tolerability of DB-1310 in subjects with advanced solid tumors.